BenevolentAI vs insitro (2026)
The two poles of AI target discovery: reason over what science already knows, or generate new biology and learn from that. BenevolentAI built a biomedical knowledge graph linking genes, proteins, diseases and compounds from literature, patents, genetics and chemistry, and it holds the most externally adjudicated evidence record in this category plus the only direct engagement with bias anyone here offers. insitro generates its own multimodal cellular data and learns causal biology from it, with the method in peer review and experimental testing built into the workflow. The failure modes are opposite and worth stating: a knowledge graph faithfully reproduces the blind spots of the literature, so neglected diseases stay neglected, while a self generating platform escapes that and inherits the biases of its own cell lines and donors instead.
- The knowledge graph assembles genes, proteins, diseases and compounds with their relationships from literature, patents, genetics and chemistry, so the reasoning is over the whole published corpus rather than one company's experiments.
- The evidence record is the most externally adjudicated in this category, earning its standing on independence rather than on volume.
- It addresses the bias question directly in its own words, which no other vendor located in this category does.
- It generates its own data rather than reasoning over what exists, converging stem cell models, genome editing and high content imaging into a platform that produces the biology it learns from.
- The core method was submitted to peer review, and the oversight is structural: model generated hypotheses about targets are tested experimentally before they advance.
- Capital position is disclosed with precision, which matters when choosing a partner for a programme that will run for years.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. BenevolentAI and insitro are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | BenevolentAI | insitro |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | Not recorded | 2018 |
| Headquarters | London, United Kingdom | South San Francisco, CA |
| Website | benevolent.com | insitro.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards BenevolentAI its top capability grade on AI Centrality and Clinical and Operational Evidence. Set against insitro, BenevolentAI grades higher on several axes, including Clinical and Operational Evidence, FDA and Regulatory Status and AI Governance and Bias Disclosure. Its thinnest published disclosure sits on AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards insitro its top capability grade on AI Centrality and Model and Technology Transparency. Set against BenevolentAI, insitro grades higher on several axes, including Model and Technology Transparency, Model Supply Chain Disclosure and AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose BenevolentAI or insitro?
On the axes where the AI Health Index separates them, BenevolentAI grades higher on several axes, including Clinical and Operational Evidence, FDA and Regulatory Status and AI Governance and Bias Disclosure, and insitro grades higher on several axes, including Model and Technology Transparency, Model Supply Chain Disclosure and AI Liability and Recourse. Neither leads on the greater share of scored axes, so the decision turns on which constraint is binding rather than on an overall winner.
Where do BenevolentAI and insitro differ most?
The widest separation the AI Health Index records between BenevolentAI and insitro is on AI Liability and Recourse, where BenevolentAI grades D and insitro grades B. That axis sits in the Regulatory and Compliance group, so it should carry the most weight for a buyer whose binding constraint is where regulatory exposure sits and who carries it.
Where do BenevolentAI and insitro grade the same?
The AI Health Index grades BenevolentAI and insitro the same on several axes, including AI Centrality, Autonomy and Oversight Model and AI Safety and PHI Stewardship. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have BenevolentAI and insitro not disclosed?
At the last review, at least one of BenevolentAI and insitro published thin or absent detail on AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
These represent the two philosophies in AI target discovery and their failure modes differ. A knowledge graph inherits the biases of the literature it was built from, so under studied diseases and populations stay under studied and the model will confidently reflect that gap. A platform generating its own data escapes that but inherits the biases of its own cell lines and donors, which neither vendor publishes. Neither holds a security attestation. BenevolentAI's commercial disclosure has thinned since it left public markets, so figures dating from its listed period should not be assumed current.